UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

Compared to the previous quarter, both analysts and management exhibited increased caution and a more defensive posture, particularly around guidance credibility and nonclinical revenue challenges.

The research team led by Senior Researchers Yoonhee Lee from the Division of Biomedical Technology and Gyogwon Koo from the ...

Fort Myers-based NeoGenomics reported mixed results for the second quarter. Revenue grew 10% over the year, but the net loss ...

KUALA LUMPUR, Malaysia, July 30, 2025 (GLOBE NEWSWIRE) -- (“BGLC”, Nasdaq: BGLC) and Fidelion Diagnostics Pte Ltd, a Singaporean company (“Fidelion”) today announced the signing of ...